Nutriband Inc.

Nutriband Inc. is a U.S.-based pharmaceutical company specializing in the development of innovative transdermal drug delivery systems. The company's core mission is to improve patient outcomes and enhance the safety profile of high-risk medications, particularly targeting the global opioid epidemic. Headquartered in Orlando, Florida, Nutriband focuses on transforming new ideas and discoveries into safer pharmaceutical products.

Nutriband's primary product focus is its proprietary AVERSA™ abuse-deterrent transdermal technology. This technology is designed to incorporate aversive agents into transdermal patches to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, such as opioids. The company's lead product candidate is the AVERSA™ Fentanyl Transdermal System, an abuse-deterrent fentanyl patch. Nutriband also has other products in its development pipeline, including AVERSA™ Buprenorphine and AVERSA™ Methylphenidate. Additionally, the company operates through subsidiaries, offering contract research and development services via 4P Therapeutics and previously contract manufacturing services through Pocono Pharmaceutical, a majority stake of which was sold in late 2025.

Led by Founder and CEO Gareth Sheridan, Nutriband is actively progressing its lead product, AVERSA™ Fentanyl, towards FDA approval, with a target New Drug Application (NDA) filing in 2026. The company recently announced the selection of a commercial brand name for this product. In recent corporate developments, Nutriband reported revenue growth in its Q2 2026 financial update and secured approval for the distribution and sale of its AI Kinesiology Tapes in Costa Rica in March 2026.